Abstract:Abstract This study examines how mutations in the TP53 gene, specifically gain-of-function (GOF) mutations, impact the subtyping and stratification of pancreatic ductal adenocarcinoma (PDAC). In addition, it investigates the underlying mechanisms as well as the potential therapeutic implications.TP53 mutations/deletions are present in 60-75 % of cases in PDAC. The most common mutations are three specific hotspot missense mutations (misp53) found at codons R273H, R248W, and R175H. Several studies indicate that these misp53 mutants, despite losing their tumor suppressive function, acquire new oncogenic effects promoting disease aggressiveness and resistance to conventional therapies. Recent findings show that misp53 mutants are associated with a poorly differentiated metastatic subtype in PDAC. However, it is unclear how distinct misp53 mutants, such as misp53R273H, affect PDAC progression and therapy resistance and whether different mutants exert distinct functions. In this study, we explore misp53R273H- and misp53R248W-driven subtype-specificity and functions in PDAC aggressiveness by exploiting transcriptomics, genomic binding and regulation, controlled functional pathways and potential therapeutic targets. By combining cell line-based RNA- and ChIP-seq data we report that misp53R273H associates with and fuels basal-like (BL) neoplastic features by a potential regulation of cell cycle progression. Preclinical mouse models underpinned these findings by connecting misp53R273H tumors to metastatic spread. Generation of constitutive knockdown cell lines and corresponding overexpression assays could support these findings by bridging a loss of misp53R273H to the more favorable classical subtype properties. Of note, co-immunoprecipitation coupled to mass spectrometry analysis revealed misp53-specific and common hotspot mutant interaction partners: for instance, proteins of the group of chromatin remodelers or the ubiquitination pathway that could serve as a mechanistic foundation for misp53-specific functional outcomes. Further, implementation of a large-scale drug screen, flow cytometry and protein expression analyses revealed insights in the potential misp53-specific regulated pathways and therapeutic vulnerabilities, which strongly correlate to cell cycle progression and thus to the previous results. Integrating these findings with preclinical mouse studies, patient-derived xenograft cell lines and publicly available patient data sets strengthens the reported results and highlights their translational relevance. In conclusion, this study clearly demonstrates that hotspot misp53 mutants play a critical role in influencing PDAC subtype-specification and disease aggressiveness. In particular, misp53R273H was associated with BL aggressiveness and cell cycle progression. The ultimate aim of the study is to identify misp53 mutant-specific patient stratification to broaden individualized therapy options. Citation Format: Laura Urbach, Lena Wieland, Frederike Penz, Lukas Klein, Jennifer Appelhans, Christof Lenz, Carolin Schneider, Schneider Günter, Ramona Schulz-Heddergott, Volker Ellenrieder, Elisabeth Heßmann, Shiv K. Singh. Elucidation of misp53-driven subtype specification and functions in pancreatic cancer [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Pancreatic Cancer; 2023 Sep 27-30; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(2 Suppl):Abstract nr C090.

Abstract 1035: VCP/p97 promotes pancreatic cancer growth by enhancing mutant p53 activity

Valosin-Containing Protein Stabilizes Mutant p53 to Promote Pancreatic Cancer Growth

Abstract 1037: Targeting the RBM38-EIF4E Complex to Increase Wild-Type P53 As a Novel Cancer Therapeutic Strategy

Abstract B087: Mutant-p53 amplifies Cxcl1 expression from distal enhancers blunting immune checkpoint inhibition efficacy in pancreatic cancer

Mutant p53 Exploits Enhancers to Elevate Immunosuppressive Chemokine Expression and Impair Immune Checkpoint Inhibitors in Pancreatic Cancer

VCP/p97/Cdc48, A Linking of Protein Homeostasis and Cancer Therapy.

VCP/p97, a pleiotropic protein regulator of the DNA damage response and proteostasis, is a potential therapeutic target in KRAS-mutant pancreatic cancer

Abstract C056: The initiation and progression of pancreatic ductal adenocarcinoma through a p53 lens

Specific mutations in the D1–D2 linker region of VCP/p97 enhance ATPase activity and confer resistance to VCP inhibitors

Abstract 1729: MG53 suppresses the tumor growth via transcriptional inhibiting the expression of KIF11 in pancreatic cancer

Abstract 1173: AKT-mTOR Pathway Mediates Mutant P53 Gain-of-function by Inhibiting Autophagy

Multifaceted role for p53 in pancreatic cancer suppression

Abstract 2988: Loss of Rbm38 Cooperates with Mutant P53 to Promote Lymphomagenesis Through Downregulation of Pten

Abstract A054: PP2A activation alters macropinosome processing in pancreatic cancer cells leading to metabolic stress and cancer cell death

Mutant P53r270h Drives Altered Metabolism and Increased Invasion in Pancreatic Ductal Adenocarcinoma.

Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 pathway inhibitors, nutraceuticals and alter metabolic properties

Abstract C090: Elucidation of misp53-driven subtype specification and functions in pancreatic cancer

Abstract A15: Elucidating the Role of P53 in the Cellular Origins of Pancreatic Cancer Development

Mutant p53 achieved Gain-of-Function by promoting tumor growth and immune escape through PHLPP2/AKT/PD-L1 pathway

Abstract 4374: PP2A-B56α in nutrient scavenging: Tipping the balance from macropinocytosis to cell death in pancreatic cancer

Abstract 2585: Mutant P53 Gains Oncogenic Functions Through a Cytosolic DNA Response